Laurion Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Laurion Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$272K	Buy	+506	New	+$259K	0.01%	372
2023 Q4	–	Sell	-16,028	Closed	-$2.34M	–	554
2023 Q3	$2.34M	Buy	+16,028	New	+$3.02M	0.01%	324
2023 Q2	–	Sell	-928	Closed	-$225K	–	662
2023 Q1	$225K	Buy	+928	New	+$253K	﹤0.01%	378
2020 Q1	–	Sell	-135,797	Closed	-$12.4M	–	962
2019 Q4	$12.4M	Buy	135,797 +131,630	+3,159%	+$12.8M	0.1%	190
2019 Q3	$359K	Buy	+4,167	New	+$391K	﹤0.01%	833

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Laurion Capital Management's MDGL Position: Q2 2026 in Review

Laurion Capital Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 506 shares worth $272K. The stake represents 0.01% of the portfolio and ranks #372 among its holdings. This is a return to the name: Laurion Capital Management previously reported a position in MDGL as recently as Q3 2023.

Laurion Capital Management first reported a position in MDGL in Q3 2019 and has held it in 5 quarters since. The position peaked at $12.4M in Q4 2019. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Laurion Capital Management held 506 shares of Madrigal Pharmaceuticals worth $272K as of Q2 2026.
Madrigal Pharmaceuticals was a new Laurion Capital Management position in Q2 2026.
Madrigal Pharmaceuticals made up 0.01% of Laurion Capital Management's portfolio in Q2 2026, its #372 holding.
Laurion Capital Management first reported a position in Madrigal Pharmaceuticals in Q3 2019 and has held it in 5 quarters since.
Laurion Capital Management's Madrigal Pharmaceuticals position peaked at $12.4M in Q4 2019.
413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.